Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31211694 | 1.00 | CA1 (0.40) | CA1KDM1ATSHRTDP1ATM | |
| SCHEMBL9377819 | 0.80 | GFER (0.36) | TSHRTDP1ATMHTR2AHTR2C | |
| SCHEMBL9380997 | 0.80 | MEN1 (0.40) | TSHRTDP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24111077 | 0.80 | MEN1 (0.40) | TSHRTDP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9379626 | 0.80 | ESR2 (0.38) | CA1KDM1AALDH1A1MAPT | |
| SCHEMBL23842647 | 0.80 | RIPK1 (0.33) | — | |
| SCHEMBL20254551 | 0.79 | HTR2A (0.37) | KDM1ASLC6A2HTR2AHTR2CSLC6A4 | |
| SCHEMBL1178805 | 0.79 | MEN1 (0.38) | TSHRMAPTPRCPGAA | |
| SCHEMBL9378182 | 0.78 | CA1 (0.46) | CA1KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL10066948 | 0.77 | HPGD (0.41) | TDP1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0295695-B1 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS (JP) | 1994-06-08 | — | — | EP | claimed |
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-12 | — | — | US | disclosed |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| US-20220242870-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | VORONOIBIO INC. (KR) | 2022-08-04 | — | — | US | disclosed |
| EP-3971190-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2022-03-23 | — | — | EP | disclosed |
| US-20210332058-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210284647-A1 | N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES | VORONOI CO., LTD (KR) | 2021-09-16 | — | — | US | disclosed |
| US-20210284647-A1 | N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES | VORONOI CO., LTD (KR) | 2021-09-16 | — | — | US | disclosed |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20190300537-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2019-10-03 | — | — | US | disclosed |
| WO-2018107060-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| WO-2016185423-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-11-24 | — | — | WO | disclosed |
| EP-0295695-B1 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-4990529-A | Nervous system disorder | MITSUI TOATSU CHEMICALS (JP) | 1991-02-05 | — | — | US | disclosed |
| US-4839376-A | Pyrazoline derivatives for treating cerebrovascular diseases | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0295695-A2 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1988-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | CA1 3485/4885KDM1A 460/4885TSHR 843/4885 |
| US-20210332058-A1 | Compounds, Compositions and Methods | BAX, CASP3, CASP8 | CA1 620/4885KDM1A 4571/4885TSHR 4796/4885 |
| US-20220242870-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | CDK4, CDK6, CDK16 | CA1 4416/4885KDM1A 1934/4885TSHR 2922/4885 |
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | CA1 4241/4885KDM1A 2716/4885TSHR 2948/4885 |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | MAP3K19, MAP3K20, MAP3K1 | CA1 3569/4885KDM1A 482/4885TSHR 797/4885 |
| US-20190300537-A1 | Compounds, Compositions and Methods | BAX, CASP3, CASP8 | CA1 620/4885KDM1A 4571/4885TSHR 4796/4885 |
| US-20210284647-A1 | N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES | MYLK3, MINK1, PLK2 | CA1 4777/4885KDM1A 899/4885TSHR 3374/4885 |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | CA1 3569/4885KDM1A 482/4885TSHR 797/4885 |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | CA1 3485/4885KDM1A 460/4885TSHR 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.